Wed, 30th Dec 2020 08:15
LONDON, Dec 30 (Reuters) - The AstraZeneca-Oxford COVID-19
vaccine approved by Britain on Wednesday should be effective
against a rapidly spreading new variant of the virus,
AstraZeneca's Chief Executive Pascal Soriot said.
"Our belief at this point is that this vaccine should be
effective against the variant," he told BBC radio.
(Reporting by Paul Sandle, editing by William James)
(Alliance News) - AstraZeneca PLC on Thursday said that the EU approved its prescription medicine Truqap, in combination with hormonal therapy Faslode...
(Alliance News) - AstraZeneca PLC on Tuesday said findings from a breast cancer drug trial showed that Truqap did not meet its primary endpoints.
(Alliance News) - London's FTSE 100 is called to open higher on Tuesday, taking confidence from a decent showing for US equities overnight, with infla...
(Sharecast News) - AstraZeneca announced on Tuesday that the phase three 'CAPItello-290' trial for 'Truqap', or capivasertib, in combination with pacl...
(Alliance News) - AstraZeneca PLC on Monday said it secured a new US approval for cancer treatment Imfinzi, also known as durvalumab, hailing an "impo...
Astrazeneca (AZN)